See if Hyalomatrix helps heal venous leg ulcers faster when added to standard care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, randomized trial conducted at multiple centers to compare standard of care (SOC) versus SOC plus Hyalomatrix for venous leg ulcers. Participants are randomly assigned to either SOC alone or SOC with Hyalomatrix, with a crossover option for those not fully healed after about 84 days. Those crossing over receive weekly Hyalomatrix applications for up to 12 visits while continuing follow-up. The study also collects data to support insurance reimbursement decisions as a post-marketing assessment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or Female, 18 years of age or older
2. Subject has a medical diagnosis of venous leg ulcer or venous insufficiency with a lower extremity wound
3. Subject has a venous leg ulcer present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
4. Subject has a venous leg ulcer with a historical wound measurement showing less than 25% healing within 14 days prior to screening
5. Subject has a venous leg ulcer with screening wound measurement showing less than 25% healing within 14 days prior to randomization
6. Subject has a venous leg ulcer without infection or clinically visible exposed bone
7. Index wound is a minimum of 1 cm2 and a maximum of 30 cm2 at first treatment visit
8. Adequate circulation if wound is location on the lower extremity demonstrated by an ABI of \>0.7 and \<1.3, or TBI of \>0.6 within 30 days prior to informed consent OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to the first treatment visit.
9. Venous Leg Ulcer is being treated with compression therapy for 14 days prior to treatment visit 1
10. Index wound is free of necrotic debris prior to Hyalomatrix application
11. Female subjects of childbearing potential having a negative pregnancy test prior to randomization
12. Index wound is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
13. Subject is able and willing to follow the protocol requirements
14. Subject had signed informed consent
15. If 2 or more wounds are present, the wounds must be separated by at least 2 cm

Exclusion Criteria:

1. Subject does not have a diagnosis of venous leg ulcer or venous insufficiency with a wound located on the lower extremity
2. Subject has a known life expectancy of \<1 year
3. Subject is unable to comply with protocol treatment
4. Subject has comorbid conditions that may compromise subject safety or wound healing in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders
5. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
6. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
7. Known contraindications to tissue-engineered allograft
8. Concurrent participation in alternative clinical trial that involves investigational drug or HCT/P interfering with wound treatment and/or healing.
9. Subject is pregnant or breastfeeding
10. Subject with history of immunosuppressant treatment (systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for \>2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
11. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
12. Venous leg ulcer with active infection
13. Wound depth with visible exposed bone
14. HBOT within 14 days prior to randomization
15. Revascularization surgery on the index wound leg within 30 days of screening phase
16. Index wound suspicious of neoplasm in the opinion of the principal investigator

Where it's running

• MedCentris of Alexandria
  Alexandria, Louisiana, United States Recruiting
• MedCentris of Hammond
  Hammond, Louisiana, United States Recruiting
• MedCentris of Leesville
  Leesville, Louisiana, United States Recruiting
• MedCentris of Many
  Many, Louisiana, United States Recruiting
• MedCentris of Metairie
  Metairie, Louisiana, United States Recruiting
• MedCentris of Pineville
  Pineville, Louisiana, United States Recruiting

Study contacts

• Study coordinator: Sarah Moore
• Email: sarah.moore@sygnola.com
• Phone: 985-629-4013

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Miro3D Wound Matrix for Diabetic Foot Ulcers

  This study tests whether adding Miro3D Wound Matrix to standard care helps healing diabetic foot ulcers in adults.

  Recruiting at 6 sites Reprise Biomedical, Inc. · Phoenix, Arizona and 13 other locations · NCT07632001

• THERAVEX Tissue Care Spray Plus for Healing of Skin Wounds and Ulcers

  This observational review tests whether THERAVEX Tissue Care Spray Plus, used with standard wound care, helps heal various skin wounds and chronic ulcers in adults.

  Recruiting Biointelligent Technology Systems SL · Barcelona · NCT07617961

• PAW-hydrogel to help chronic wounds like diabetic foot and leg ulcers heal faster

  This trial will test whether a plasma-activated water–infused Carbopol® 940 hydrogel helps adults with long-standing wounds (diabetic foot, pressure, venous, arterial, or dehiscent ulcers) heal faster and have less bacteria compared with standard advanced wound care.

  Recruiting National Institute of Nuclear Research - Mexico · Ocoyoacac, State of Mexico · NCT07541196

• GORE VIABAHN FORTEGRA Venous Stent Post-Approval Study

  This study tests the GORE VIABAHN FORTEGRA Venous Stent in real-world patients with venous diseases to see how it performs after it is approved.

  Recruiting at 4 sites W.L.Gore & Associates · Darien, Connecticut and 3 other locations · NCT07538609

• Human placental membrane products plus standard care for nonhealing diabetic foot and venous leg ulcers

  This trial will try human placental membrane products together with standard wound care to help adults whose diabetic foot ulcers or venous leg ulcers have not healed.

  Recruiting BioLab Holdings · Philidelphia, Pennsylvania · NCT07364630

• Suprasorb X+PHMB Pro versus Suprasorb X+PHMB for infected venous leg ulcers

  This study will test whether Suprasorb X+PHMB Pro heals infected venous leg ulcers better than Suprasorb X+PHMB in adults with slightly to moderately draining wounds.

  Recruiting at 7 sites Lohmann & Rauscher · Bialystok and 8 other locations · NCT07211243

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.